Delos Capital — Full Portfolio
40 tracked investments · listed companies and verified rows first
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersQuan CapitalSR One Capital ManagementVivo Capital+1 more
Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area.
BiotechHealthtechLongevityMedical DevicesSan Diego, US
Qunsheng Ji(Chief Executive Officer)Curt Bradshaw(Chief Scientific Officer)Patrick Yue(Chief Medical Officer)Hailei Lu(Chief Financial Officer)
Co-investorsOrbiMedCreacion Ventures
Tulavi develops medical devices for peripheral nerve surgery, aiming to improve surgical treatment options and patient outcomes in nerve care.
HardwareHealthtechMedical DevicesMountain View, US
Farhad Khosravi(Executive Officer, Director)Fred Khosravi(Chairman & Co-Founder)inJosh Vose(Chief Executive Officer)inCorinne Bright(Executive Officer, Director)
BoardHenry Chen(Director)in
Co-investorsAscension Ventures
Verge Medical (formerly Ostial Corporation) develops medical devices for aorto-ostial vascular interventions, including the FLASH Flex aorto-ostial angioplasty system and the RoVo mechanical thrombectomy device, used by physicians for coronary and peripheral vascular cases.
HealthtechMedical Devices
Mike Buck(Chief Executive Officer)inAdam Tschida(General Manager & COO)in
Co-investorsAmed Ventures
STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients.
BiotechDeep TechHealthtechLongevityMedical Devices
Michael Luther(CEO)in
Co-investorsAscension VenturesBreakout LabsBreakout VenturesNYBC VenturesKdT Ventures
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira VenturesNextech Invest+9 more
.png)
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonRA CapitalBiotechnology Value FundSoleus Capital
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDomain Associates+8 more
Atia Vision develops OmniVu, a modular shape-changing dual-optic intraocular lens (IOL) that uses the eye's natural accommodative mechanism to restore near, intermediate, and distance vision for cataract patients.
HardwareHealthtechMedical DevicesCampbell, US
Co-investorsAmed VenturesThe Capital Partnership
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Co-investorsForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMedQuan Capital+3 more
Averna Therapeutics is a biotechnology company developing therapeutics.
BiotechDeep TechHealthtechMedical DevicesWatertown, US
Richard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)
BoardRoy Amariglio(Director)Nick Olsen(Director)inStephen Squinto(Director)inMichal Silverberg(Director)in
Co-investorsDeep InsightNovartis Venture FundOrbiMed
Non-surgical, non-pharmacologic devices to induce weight loss
Co-investorsLongitude CapitalArboretum VenturesHighland Capital PartnersSante Ventures
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)inMichael Mendelsohn, M.D.(Founder)in
Co-investorsBain CapitalDigitalis VenturesNew Enterprise Associates (NEA)Ascenta CapitalBain Capital Life SciencesBain Capital Tech Opportunities+4 more
Clover Biopharma is a commercial-stage biotechnology company that develops vaccines using its Trimer-Tag technology platform along with in-house manufacturing and commercial capabilities.
BiotechHealthtechChengdu
Peng Liang(Executive Officer, Director, Promoter)inJoshua Liang(Executive Officer, Director)in
BoardXiaodong Wang(Director)
Woburn, US
LAN BO CHEN(Executive Officer, Director)BRYAN KEANEY(Executive Officer)
BoardHENRY CHEN(Executive Officer, Director)in
Curatia Medical develops and manufactures FDA and CE-approved disposable medical devices for interventional procedures in cardiology, peripheral, neurology, and pulmonology.
Advanced ManufacturingHealthtechMedical DevicesSunnyvale, US
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.
BiotechHealthtechCambridge, US
Jingye Zhou(Founder)in
Co-investorsNew Alliance Capital
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPF-Prime CapitalSolasta VenturesAlexandria+7 more
Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.
AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US
Aaron Hurst(Founder)in
Co-investorsVoyager CapitalAlly Bridge GroupAmed VenturesAscension VenturesBain Capital Life SciencesCatalio Capital Management+2 more
Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.
HealthtechMedical DevicesCampbell, US
Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in
BoardJames Rogers(Director)Stacy Enxing Seng(Director)
Co-investorsAscension VenturesFemHealth VenturesLightstone Ventures
Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.
BiotechHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)inSteven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)in
BoardHenry Chen(Director)inTasneem Dohadwala(Director)in
Co-investorsAngel Physicians FundAscension VenturesExcelestar Ventures
Barricaid develops a bone-anchored implant designed to reduce reherniation and reoperation in patients undergoing discectomy for large annular defects.
HealthtechMedical DevicesWoburn, US
Gregory H. Lambrecht(Director)Carey Hagan(Executive Officer, Director)Cary Hagan(Executive Officer, Director)
BoardRyan Drant(Director)inJeani Delagardelle(Director)Joshua Makower(Director)
Co-investorsNew Enterprise Associates (NEA)Questa CapitalGreenspring AssociatesNew Leaf Venture Partners
Liposeuticals develops proprietary formulations of sterile injectable drugs for hospital use, focusing on anesthesiology, oncology, and infectious disease treatments.
BiotechMedical Devices
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesKorea Investment PartnersLumira VenturesLYZZ Capital+1 more
.jpeg){kind=logo}
Phanes Therapeutics develops oncology and metabolic disease therapeutics targeting cell cycle regulators and related pathways.
BiotechDeep TechHealthtechMedical DevicesSan Diego, US
Dr. Ming Wang(Founder, President and CEO)
Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.
BiotechFemTechHealthtechMedical DevicesBedford, US
AMARPREET SAWHNEY(Executive Officer, Director, Promoter)inAmar Sawhney(Founder)inNICK SVENCER(Executive Officer, Director, Promoter)FARHAD KHOSRAVI(Executive Officer, Director, Promoter)
BoardTARA BUTLER(Executive Officer, Director, Promoter)
Co-investorsAscension VenturesClavystBioFemHealth VenturesIyengar Capital PartnersAmed VenturesCatalyst Health Ventures
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)inHualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)inSimon Xi(Co-founder and CEO)inJackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsVivo CapitalAMR Action FundBoehringer Ingelheim Venture FundKorea Investment PartnersLilly Asia VenturesMatrix Capital Management+1 more
TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.
AI & Machine LearningBiotechDeep TechHealthtech
Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)
Co-investorsAvego BioScience CapitalPfizer Venture InvestmentsAgent Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.